Discoveries in Myeloproliferative Neoplasms

SAN DIEGO — First-line treatment with ruxolitinib led to “clinically meaningful” positive results versus best available therapy in patients with high-risk polycythemia vera, according to data presented at ASH Annual Meeting.

SAN DIEGO — Patients with Philadelphia chromosome-negative accelerated- or blast-phase myeloproliferative neoplasms who received allogeneic hematopoietic stem cells had a longer median OS than those who did not, according to a study.

SAN DIEGO — Lower platelet count was identified as a significant predictor for ruxolitinib-induced moderate or severe thrombocytopenia in patients with myelofibrosis, according to research presented at ASH Annual Meeting and Exposition.

SAN DIEGO — The BET inhibitor BMS986158 has continued to be well tolerated in combination with ruxolitinib and fedratinib in patients with intermediate- or high-risk myelofibrosis, according to a study presented at ASH Annual Meeting.

SAN DIEGO — Treatment with a selective PIM1 kinase inhibitor showed positive clinical reactions in a sample of 23 patients with relapsed/refractory myelofibrosis, according to preliminary data presented at ASH Annual Meeting.

SAN DIEGO — Treatment with fedratinib led to “superior” spleen volume reduction and symptom response rates in patients with myelofibrosis previously treated with ruxolitinib, according to data presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Researchers found JAK-STAT mutations in a predominance of a cohort of adults with fusion-free hypereosinophilia with features suggesting myeloid neoplasms, according to data presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Pacritinib may provide a “unique survival advantage” for patients with myelofibrosis also exhibiting moderate or severe thrombocythemia, according to data from the PERSIST-2 study, presented at ASH Annual Meeting and Exposition.

In this video, Srinivas K. Tantravahi, MBBS, MRCP(UK), discussed a case study, presented at the 14th International Congress on Myeloproliferative Neoplasms, of dizygotic twins.

Srinivas K. Tantravahi, MBBS, MRCP(UK), spoke with Healio about both nonpharmacologic interventions and pharmacologic developments for patients with myeloproliferative neoplasms.